Amgen Inc. won a U.S. court ruling that bars Teva Pharmaceutical Industries Ltd. from selling a generic version of the kidney drug Sensipar until at least 2016.
Teva can’t enter the market until the last of three patents expires, U.S. District Judge Harvey Bartle in Wilmington, Delaware, ruled today. The judge rejected Teva’s arguments that the patents are invalid.
Sensipar, whose chemical name is cinacalcet hydrochloride, generated $320 million in U.S. sales in the first nine months of last year for Amgen, the Thousand Oaks-based company said Oct. 25. Amgen, along with patent partners NPS Pharmaceuticals Inc. and Brigham & Women’s Hospital Inc. of Boston, sued in 2008 to prevent Teva from selling a copy of the medicine.
• CLICK HERE to read the Bloomberg News story.
